Loading...
XLONFARN
Market cap216mUSD
Dec 23, Last price  
165.00GBP
1D
0.00%
1Q
-21.80%
Jan 2017
-37.72%
IPO
-40.53%
Name

Faron Pharmaceuticals Oy

Chart & Performance

D1W1MN
XLON:FARN chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
-70.49%
Rev. gr., 5y
-61.50%
Revenues
0k
0200,000906,000520,0001,153,0001,49519,00000000
Net income
-31m
L+3.03%
-2,460,000-1,508,000-1,364,000-6,188,000-9,294,000-21,060,000-20,086,000-13,262,000-16,946,000-21,194,000-30,034,000-30,944,000
CFO
-24m
L+3.54%
-2,268,000-768,000-389,000-7,146,000-8,452,000-18,363,000-20,525,000-11,523,000-17,479,000-22,218,000-22,993,000-23,806,000
Earnings
Mar 11, 2025

Profile

Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company develops a pipeline of immune modulation based proprietary drug candidates for unmet need, including immuno-oncology, and organ protection and regenerative medicine. Its lead product candidates are Traumakine, an intravenous interferon beta-1a therapy for the treatment of acute respiratory distress syndrome, COVID-19, acute kidney injury, cardiac protection, solid organ transplant, and ischemia reperfusion injury; and Bexmarilimab, a novel precision cancer immunotherapy candidate for treating solid tumors, non-small cell lung carcinoma, and hematological malignancies. The company also develops Haematokine, a new chemical entity AOC3 inhibitor for the treatment of hematological malignancies and bone marrow. Faron Pharmaceuticals Oy was founded in 2003 and is headquartered in Turku, Finland.
URL
https://www.faron.com/
IPO date
Nov 17, 2015
Employees
40
Domiciled in
FI
Incorporated in
FI

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
Cost of revenue
28,594
28,228
27,245
Unusual Expense (Income)
NOPBT
(28,594)
(28,228)
(27,245)
NOPBT Margin
Operating Taxes
1,304
16
Tax Rate
NOPAT
(28,594)
(29,532)
(27,261)
Net income
(30,944)
3.03%
(30,034)
41.71%
(21,194)
25.07%
Dividends
Dividend yield
Proceeds from repurchase of equity
26,031
13,445
25,559
BB yield
-12,407.15%
-8.84%
-18.84%
Debt
Debt current
3,638
2,004
613
Long-term debt
9,686
11,581
3,134
Deferred revenue
151
Other long-term liabilities
896
1,011
152
Net debt
6,449
6,595
(3,106)
Cash flow
Cash from operating activities
(23,806)
(22,993)
(22,218)
CAPEX
(123)
(385)
(474)
Cash from investing activities
(123)
(385)
(473)
Cash from financing activities
23,983
23,478
25,590
FCF
(27,443)
(28,174)
(29,190)
Balance
Cash
6,875
6,990
6,853
Long term investments
Excess cash
6,875
6,990
6,853
Stockholders' equity
(169,363)
(140,892)
(113,458)
Invested Capital
168,209
143,696
120,226
ROIC
ROCE
2,477.82%
EV
Common stock shares outstanding
69
50,724
50,724
Price
3.05
1.67%
3.00
12.15%
2.68
2.88%
Market cap
210
-99.86%
152,172
12.15%
135,687
14.16%
EV
6,659
158,767
132,581
EBITDA
(28,248)
(27,928)
(26,938)
EV/EBITDA
Interest
1,400
235
Interest/NOPBT